Summary & Overview
HCPCS J1205: Injection, Chlorothiazide Sodium, per 500 mg
HCPCS Level II code J1205 denotes injection of chlorothiazide sodium, billed per 500 mg unit. This code captures administration of a parenteral thiazide diuretic used in acute care and infusion settings when oral therapy is not feasible. Nationally, accurate coding for parenteral diuretics affects hospital pharmacy billing, drug utilization monitoring, and payer reimbursement for inpatient and outpatient infusion services.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for when parenteral chlorothiazide is used, typical sites of service, and what to expect in payer coverage and billing practice. The publication also outlines benchmarks and policy-relevant considerations affecting coverage and claims processing for injectable diuretics.
The report covers coding specifics for J1205, common service lines and clinical indications for parenteral thiazide therapy, and an overview of payer approaches to coverage and reimbursement. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1205 describes an injectable formulation of chlorothiazide sodium, billed per 500 mg unit. The service represents administration of an intravenous or intra-arterial diuretic agent used in clinical settings where parenteral thiazide therapy is indicated.
Service Type: Injectable medication administration
Typical Site of Service: Hospital inpatient, hospital outpatient infusion center, or acute care settings where parenteral diuretic therapy is provided. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a neonate or young infant with symptomatic congenital or hereditary edema and impaired renal sodium handling who requires intravenous administration of a thiazide diuretic when oral therapy is not feasible. Presentation may include generalized edema, hyponatremia-related symptoms, or inability to tolerate oral medications due to vomiting or enteral access limitations. The medication J1205 (injection, chlorothiazide sodium, per 500 mg) is prepared in pharmacy under sterile conditions and delivered to the neonatal intensive care unit (NICU) or pediatric inpatient floor. The clinical workflow includes order entry with indication and weight-based dosing, pharmacy compounding and verification, bedside administration by a registered nurse with access-line or peripheral IV compatibility checks, monitoring of intake/output, serum electrolytes (sodium, potassium), vital signs, and urine output. Documentation includes the drug name and NDC if applicable, lot number, dose administered, route, time, site of administration, and any immediate adverse reactions. Typical sites of service are the NICU, pediatric inpatient unit, or hospital outpatient infusion center when intravenous therapy is required and oral route is contraindicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special modifier applies to the service. |